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Abstract.
Background: Abnormal insulin signaling in the brain has been linked to Alzheimer’s disease (AD).
Objective: To evaluate whether cerebrospinal fluid (CSF) insulin levels are associated with cognitive performance and CSF
amyloid- and Tau. Additionally, we explore whether any such association differs by sex or APOE 4 genotype.
Methods: From 258 individuals participating in the Parelsnoer Institute Neurodegenerative Diseases, a nationwide multicen-
ter memory clinic population, we selected 138 individuals (mean age 66 ± 9 years, 65.2% male) diagnosed with subjective
cognitive impairment (n = 45), amnestic mild cognitive impairment (n = 44), or AD (n = 49), who completed a neuropsycho-
logical assessment, including tests of global cognition and memory performance, and who underwent lumbar puncture. We
measured CSF levels of insulin, amyloid-1-42, total (t-)Tau, and phosphorylated (p-)Tau.
∗Correspondence to: Professor Geert Jan Biessels, Department
of Neurology, G03.232, University Medical Centre Utrecht, PO
Box 85500, 3508 GA Utrecht, the Netherlands. Tel.: +31 88 755
9490; Fax: +31 30 254 2100; E-mail: g.j.biessels@umcutrecht.nl.
ISSN 1387-2877/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
310 S.L.C. Geijselaers et al. / CSF Insulin and Alzheimer’s Disease
Results: CSF insulin levels did not differ between the diagnostic groups (p = 0.136). Across the whole study population, CSF
insulin was unrelated to cognitive performance and CSF biomarkers of AD, after adjustment for age, sex, body mass index,
diabetes status, and clinic site (all p≥ 0.131). Importantly, however, we observed effect modification by sex and APOE
4 genotype. Specifically, among women, higher insulin levels in the CSF were associated with worse global cognition
(standardized regression coefficient –0.483; p = 0.008) and higher p-Tau levels (0.353; p = 0.040). Among non-carriers of the
APOE 4 allele, higher CSF insulin was associated with higher t-Tau (0.287; p = 0.008) and p-Tau (0.246; p = 0.029).
Conclusion: Our findings provide further evidence for a relationship between brain insulin signaling and AD pathology.
It also highlights the need to consider sex and APOE 4 genotype when assessing the role of insulin.
Keywords: Alzheimer’s disease, cerebrospinal fluid, cognition, epidemiology, insulin
INTRODUCTION
Over the last decades, a growing body of evi-
dence from in vitro experiments, animal models, and
observations in patients has linked abnormal insulin
signaling to Alzheimer’s disease (AD) [1–4]. Multi-
ple pathways may account for this, which have been
extensively reviewed elsewhere [1–4]. Insulin is, for
example, believed to interfere with the metabolism of
amyloid- (A) and tau [3].
At present, brain insulin signaling cannot be
measured directly in humans in vivo. Evidence of
deficient insulin signaling in patients with AD there-
fore stems from postmortem brain studies showing
fewer insulin receptors and decreased downstream
signaling activity in the brains of individuals with
AD as compared to age-matched controls [5]. To
overcome the lack of direct measures, previous
population-based studies used blood-derived mark-
ers of peripheral insulin resistance as a possible
indicator of deficient brain signaling. These studies
generally showed that hyperinsulinemia [6–8] and
insulin resistance [6, 9, 10] are associated with cog-
nitive impairment [8–10] and risk of AD [6–8, 10],
although these associations might be limited to, or
most prominent in, women [9] and non-carriers of the
apolipoprotein E 4 (APOE 4) allele [7, 9, 10]. More
recently, blood-derived markers of insulin resistance
have also been related to cerebrospinal fluid (CSF)
biomarkers of AD in cognitively asymptomatic indi-
viduals, but these associations depended on APOE
4 genotype [11, 12].
Evidently, peripheral insulin levels and insulin
sensitivity may not accurately reflect the cerebral situ-
ation [13]. Transport of insulin across the blood-brain
barrier decreases with increasing insulin resistance
[14] and there appears to be local production of
insulin in the brain [15]. This may explain why there is
no clear correlation between plasma and CSF insulin
levels [15]. Published data on CSF insulin in relation
to AD are, however, scarce, show variable results, and
generally (with one exception [16]) did not account
for the potential modifying effects of sex and APOE
4 genotype [17–21]. At the same time, an increasing
number of clinical trials have shown that intranasal
insulin administration enhances memory function (in
AD) (e.g., [22–26]), particularly in women and those
without APOE 4 [24–26]. Here, we made use of
a standardized multicenter memory clinic popula-
tion to assess the associations of CSF insulin with
cognitive performance and CSF biomarkers of AD
[i.e., A1-42, Tau, and phosphorylated Tau (p-Tau)]
and explored whether any such association differed
by sex or APOE 4 genotype. We hypothesized
that higher CSF insulin levels, likely reflecting cere-
bral insulin resistance, would be associated with AD
pathology.
METHODS
Study population
This study was based on data from the Parelsnoer
Institute: Neurodegenerative Diseases, a collabora-
tion between the eight Dutch University Medical
Centres (http://www.parelsnoer.org) [27]. In short,
the Pearl Neurodegenerative Diseases focuses on the
role of biomarkers in the early diagnosis, differential
diagnosis, and prognosis of neurodegenerative dis-
eases, in particular AD [27]. Eligible for inclusion
are individuals referred to one of the eight academic
memory clinics for the evaluation of cognitive prob-
lems, with a Clinical Dementia Rating scale of 0, 0.5,
or 1, and a Mini-Mental State Examination (MMSE)
of 20 or higher. Harmonized protocols are used to
collect clinical data and biomaterials from patients
who provide written informed consent [27]. Indi-
viduals are classified as having subjective cognitive
impairment (SCI), mild cognitive impairment (MCI),
or dementia, using a diagnostic procedure that is
harmonized across the participating centers [27].
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For the present cross-sectional analyses, we used
data from the first 258 patients who were enrolled
in the database between March 2009 and December
2013 and successfully underwent lumbar puncture,
which is optional for participants in this study. From
these, we selected those patients diagnosed with AD
or its potential prodromal stages (i.e., amnestic MCI
or SCI), thereby excluding individuals with non-
amnestic MCI (n = 26) or other types of dementia
(n = 37). To distinguish amnestic from non-amnestic
MCI, objective memory deficits were defined as age-,
sex-, and educational level-adjusted immediate or
delayed recall scores on the 15 Word-Auditory Verbal
Learning Test (AVLT) [28, 29] that were at least 1.5
standard deviation below the normative mean [30].
Individuals in whom the presence of objective deficits
could not be verified due to missing data on the AVLT
or educational level were excluded (n = 3).
CSF insulin could be determined for 160 out of the
192 patients (83.3%) who underwent lumbar punc-
ture and were eligible for the present study. In the
other 32 patients, there was too little CSF left after
A1-42, Tau, and p-Tau assays. Of the 160 patients,
5 (3%) had no data on APOE 4 genotype and
were therefore excluded from the study sample. An
additional 17 individuals were excluded because of
missing data on demographic and clinical variables,
primarily body mass index (n = 13) and diabetes sta-
tus (n = 8; Supplementary Table 1), resulting in a final
study population of 138 individuals (n = 133 for anal-
yses with cognitive performance). Individuals who
were excluded because of missing data did not differ
from those who were included in the present analyses
(Supplementary Table 1).
The Pearl Neurodegenerative Diseases was
approved by the Medical Ethics Review Committee
of the VU University Medical Centre, and written
informed consent was obtained from patients enrolled
in the dataset.
Cerebrospinal ﬂuid measures
Lumbar puncture was performed at the L3/L4
or L4/L5 intervertebral space and 3 ml of the
collected CSF was aliquoted in 0.5 ml samples,
which were stored at –80◦C [27]. From these sam-
ples, A1-42, Tau, and p-Tau were measured using
Innotest® Enzyme-Linked Immunosorbent Assays
(Innogenetics, Ghent, Belgium) [27]. These assays
were performed at the Neurochemistry Laboratory
of the department of Clinical Chemistry of the VU
Medical Centre Amsterdam according to described
procedures [27]. The samples were analyzed all at
once, using the same batch of reagents.
CSF levels of insulin were measured at the same
department, in the Endocrine Laboratory, in the CSF
volume that remained after aliquots had been taken
for A1-42, Tau, and p-Tau assays, a leftover vol-
ume that ranged between 75 and 150L per patient.
CSF insulin levels were measured using an ultrasen-
sitive radioimmunoassay (EMD Millipore, Bellerica,
MA) with a detection limit of 1.2 pmol/L. The limited
amount of CSF available prevented us from measur-
ing insulin in duplicate. Note that patients were not
required to fast prior to lumbar puncture.
Cognitive performance
As part of the diagnostic workup, patients com-
pleted a standardized battery of cognitive tests [27].
We selected neuropsychological tests that reflect
global cognition (i.e., MMSE [31], a screening test)
and memory performance (i.e., AVLT [28, 29]), the
latter because insulin signaling has been primarily
related to memory performance [32, 33]. Total imme-
diate and delayed recall scores of the ALVT were
combined into one composite memory score. To this
end, raw test scores were transformed into z-scores
and averaged.
Covariates
A detailed description of the covariates (i.e., edu-
cational level, medical history, and lifestyle factors)
is provided in the Supplementary Material.
Statistical analyses
Differences in demographic and clinical character-
istics across the diagnostic groups (i.e., SCI, aMCI,
and AD) were evaluated using analysis of variance
for continuous variables and chi-square tests for cat-
egorical variables. Because there are currently limited
data on variables that determine CSF levels of insulin,
we used univariate linear regression to explore the
association between CSF insulin and the available
set of demographic and clinical variables known to
be associated with cognitive performance (i.e., age,
sex, educational level, blood pressure, body mass
index, diabetes, cardiovascular or cerebrovascular
disease, smoking behavior, and alcohol consump-
tion). In these analyses, CSF insulin was taken as the
dependent variable and assumptions of linear regres-
sion were verified prior to analyses. Variables that
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showed a significant association with CSF insulin
(p-value < 0.05) were considered as potentially
confounding factors in subsequent multivariate
analyses.
With use of analysis of covariance, we exam-
ined whether CSF insulin levels differed between
the diagnostic groups, independent of the identified
potentially confounding variables. Multiple linear
regression analyses were then conducted to examine
the association of CSF insulin with cognitive perfor-
mance (i.e., MMSE and composite memory score)
and CSF biomarkers of AD (i.e., A1-42, Tau, and
p-Tau). In these main analyses, which were per-
formed across and within each diagnostic group, CSF
insulin was the independent variable. Two predefined
models of adjustment were used (model 1: clinic site;
model 2: model 1 + age and sex). The third model also
included those variables being associated with CSF
insulin in the univariate analyses.
Multiple interaction terms (i.e., CSF insulin * sex
and CSF insulin * APOE 4 carriership) were used to
explore whether any association between CSF insulin
and cognitive performance or Alzheimer pathology
differed by sex or APOE 4 genotype. Likewise,
we examined whether any association differed by
the presence of diabetes given that diabetes is char-
acterized by abnormal insulin signaling, at least in
the periphery [34]. In case of significant interaction,
stratified analyses were performed. We additionally
evaluated whether any of the univariate associations
observed between CSF insulin and demographic or
clinical characteristics differed by sex or APOE 4
genotype.
As a sensitivity analysis, we reanalyzed the data
with exclusion of individuals previously diagnosed
with diabetes.
All analyses were performed with use of SPSS
for Windows, version 23.0 (IBM SPSS, IBM Corp,
Armonk, NY, USA). Levels of CSF insulin, Tau, and
p-Tau were transformed with the natural logarithm
prior to the analyses. A two-sided p-value < 0.05 was
considered significant, except for interaction analy-
ses where the significance level was set at 0.10 to
compensate for the loss of statistical power in these
analyses [35]. No adjustments were made for multiple
testing [36].
RESULTS
Table 1 shows the demographic and clinical char-
acteristics of the study population as a whole, by sex,
and by diagnostic group [i.e., SCI (n = 45); aMCI
(n = 44), and AD (n = 49)]. Overall, patients were in
late adulthood (66 ± 9 years), with a slight male pre-
dominance (65.2%). Men had somewhat unhealthier
lifestyle variables than women and more frequently
reported a history of cardiovascular disease. Cere-
brovascular disease was, however, equally distributed
between the sexes. Of note, the cardiovascular risk
profile was similar across the diagnostic groups,
except for the presence of diabetes, which was least
common in the SCI group.
CSF insulin in relation to demographic
and clinical variables: Basic ﬁndings
Table 2 shows the univariate associations of clin-
ical and demographic variables with CSF levels of
insulin in the total study population. Diabetes sta-
tus and higher body mass index were associated with
higher CSF insulin levels, whereas carriers of the
APOE 4 allele had lower CSF insulin in comparison
with non-carriers There were no significant associa-
tions with the other variables.
Multiplicative interaction analyses showed that sex
modified the univariate association between diabetes
and CSF insulin in that diabetes was more strongly
associated with higher CSF insulin levels in men than
women. Sex also modified the association between
APOE 4 and CSF insulin. Specifically, APOE 4
carriership was more strongly associated with lower
CSF insulin levels in women than men, although the
association between APOE 4 and CSF reached sta-
tistical significance in neither of the sexes. APOE
4 carriership itself, in turn, modified the univariate
association between diabetes and CSF insulin in that
diabetes was only associated with higher CSF insulin
levels in non-carriers of the APOE 4 allele. Please
note that CSF insulin levels did not differ between
sexes and diabetes was not more common among men
(Table 1). Likewise, APOE 4 genotype did not differ
between sexes (Table 1).
CSF insulin in the diagnostic groups of cognitive
impairment
Median (interquartile range) levels of CSF insulin
in individuals with SCI, aMCI, and AD were
3.77 pmol/L (3.34–4.39), 3.61 pmol/L (3.22–4.36),
and 3.98 pmol/L (3.57–4.77), respectively. Despite
the seemingly higher levels of CSF insulin in AD,
CSF insulin did not differ significantly between
the groups (p = 0.136). The linear trend across the
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Table 1
Demographic and clinical characteristics of the study population as a whole and stratified by sex and diagnostic group
Total Men Women p-value for SCI aMCI AD p-value for
(n = 138) (n = 90) (n = 48) difference (n = 45) (n = 44) (n = 49) trend
Age (y) 66 ± 9 66 ± 9 65 ± 10 0.564 62 ± 9 67 ± 9 68 ± 9 <0.001
Male 90 (65.2%) . . . . . . . . . 30 (66.7%) 30 (68.2%) 30 (61.2%) 0.573
Educational level
Low 32 (23.2%) 21 (23.3%) 11 (22.9%) 10 (22.2%) 11 (25.0%) 11 (22.4%)
Middle 52 (37.7%) 27 (30.0%) 25 (52.1%) 0.020 16 (35.6%) 19 (43.2%) 17 (34.7%) 0.962
High 54 (39.1%) 42 (46.7%) 12 (25.0%) 19 (42.2%) 14 (31.8%) 21 (42.9%)
SBP (mmHg)∗ 145 ± 19 145 ± 19 146 ± 20 0.933 142 ± 19 145 ± 17 149 ± 22 0.127
DBP (mmHg)∗ 84 ± 10 85 ± 10 83 ± 10 0.325 83 ± 11 84 ± 7 84 ± 12 0.470
BMI (kg/m2) 25.2 ± 3.2 25.6 ± 3.2 24.7 ± 3.1 0.113 25.7 ± 3.2 25.3 ± 3.0 24.8 ± 3.4 0.194
Diabetes 16 (11.6%) 12 (13.3%) 4 (8.3%) 0.382 2 (4.4%) 5 (11.4%) 9 (18.4%) 0.036
Cardiovascular disease 43 (31.2%) 38 (42.2%) 5 (10.4%) <0.001 17 (37.8%) 13 (29.5%) 13 (26.5%) 0.244
Cerebrovascular disease 17 (12.3%) 12 (13.3%) 5 (10.4%) 0.620 7 (15.6%) 3 (6.8%) 7 (14.3%) 0.877
APOE 4 carrier 81 (58.7%) 52 (57.8%) 29 (60.4%) 0.766 20 (44.4%) 31 (70.5%) 30 (61.2%) 0.110
Smoking behavior∗
Never 58 (43.0%) 29 (32.2%) 29 (60.4%) 16 (35.6%) 19 (45.2%) 23 (47.9%)
Former 56 (41.5%) 42 (46.7%) 14 (29.2%) 0.005 23 (51.1%) 15 (35.7%) 18 (37.5%) 0.454
Current 21 (15.6%) 17 (18.9%) 4 (8.3%) 6 (13.3%) 8 (19.0%) 7 (14.6%)
Alcohol consumption∗ 110 (80.3%) 78 (86.7%) 32 (66.7%) 0.003 37 (82.2%) 35 (81.4%) 38 (77.6%) 0.568
CSF insulin (pmol/L) 3.79 [3.37–4.52] 3.85 [3.43–4.60] 3.65 [3.12–4.40] 0.234 3.77 [3.34–4.39] 3.61 [3.22–4.36] 3.98 [3.57–4.77] 0.059
CSF A1-42 (ng/L) 678 ± 281 701 ± 301 636 ± 237 0.172 835 ± 244 656 ± 279 554 ± 250 <0.001
CSF Tau (ng/L) 421 [229-633] 397 [231-619] 494 [222-707] 0.418 229 [176-354] 485 [267-651] 544 [401-864] <0.001
CSF p-Tau (ng/L) 55 [36-77] 54 [36-76] 57 [39-86] 0.663 36 [23-55] 58 [40-83] 71 [53-89] <0.001
MMSE (score)∗ 26 ± 3 27 ± 3 26 ± 3 0.111 28 ± 2 27 ± 3 24 ± 3 <0.001
AVLT (words)
Total immediate recall∗ 30 ± 11 30 ± 11 31 ± 13 0.408 41 ± 10 26 ± 7 25 ± 8 <0.001
Delayed recall∗ 4 ± 4 4 ± 3 5 ± 4 0.418 8 ± 3 2 ± 2 3 ± 3 <0.001
Data are presented as n (%), mean ± SD, or median [IQR]. ∗Data not available from all participants (n = 137 for alcohol consumption; n = 136 for AVLT total immediate recall; n = 135 for SBP,
DBP, smoking behavior, MMSE, and AVLT delayed recall). SCI, subjective cognitive impairment; aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s dementia; SBP, systolic blood
pressure; DBP, diastolic blood pressure; BMI, body mass index; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; AVLT, 15 Word-Auditory Verbal Learning Test.
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Table 2
Univariate associations of clinical and demographic characteristics with CSF insulin levels in the whole study population and stratified according to sex and APOE 4 genotype where applicable
n  p-value for  p-value for
(nmax = 138) interaction interaction with
with sex APOE 4 carriership
Age 138 0.012 (–0.158; 0.181) 0.315 . . . 0.792 . . .
Sex
male versus female 138 0.214 (–0.139; 0.566) . . . . . . 0.540 . . .
Educational level
medium versus low 138 –0.253 (–0.698;0.193) 0.886 . . . 0.904 . . .
high versus medium 0.068 (–0.317; 0.453) 0.477 . . . 0.432 . . .
high versus low –0.185 (–0.627; 0.258) 0.453 . . . 0.569 . . .
SBP 135 0.101 (–0.070; 0.271) 0.240 . . . 0.562 . . .
DBP 135 0.039 (–0.132; 0.211) 0.369 . . . 0779 . . .
BMI 138 0.261 (0.097; 0.425) 0.756 . . . 0.326 . . .
Diabetes 138 1.152 (0.662; 1.642) <0.001 Men: 2.232 (1.401; 3.063) 0.012 Carriers: 0.528 (–0.230; 1.285)
yes versus no Women: 0.657 (0.053; 1.261) Non-carriers: 1.706 (1.065; 2.346)
Cardiovascular disease
yes versus no 138 0.211 (–0.153; 0.574) 0.492 . . . 0.704 . . .
Cerebrovascular disease
yes versus no 138 0.089 (–0.425; 0.603) 0.360 . . . 0.784 . . .
APOE 4 genotype 138 –0.547 (–1.078; –0.016) 0.092 Men: –0.192 (–0.698; 0.313) . . . . . .
carriers versus non-carriers Women: –1.118 (–2.295; 0.059)
Smoking behavior
former versus never 135 0.121 (–0.252; 0.494) 0.455 . . . 0.400 . . .
current versus former –0.025 (–0.534; 0.484) 0.319 . . . 0.519 . . .
current versus never 0.096 (–0.410; 0.603) 0.615 . . . 0.520 . . .
Alcohol consumption Carriers: 0.395 (–0.301; 1.091)
yes versus no 137 –0.080 (–0.506; 0.347) 0.650 . . . 0.090 Non-carriers: –0.365 (–0.910; 0.179)
Data are presented as standardized regression coefficients  (95% confidence intervals) for continuous variables and between-group differences (95% confidence intervals) for categorical variables,
the latter expressed in standard deviations of cerebrospinal fluid insulin levels. p-values are derived from interaction analyses with sex and APOE 4 carriership. Insulin levels were transformed
with the natural logarithm prior to analysis. CSF, cerebrospinal fluid; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
S.L.C. Geijselaers et al. / CSF Insulin and Alzheimer’s Disease 315
Table 3
Association of CSF insulin levels with cognitive performance
Total SCI aMCI AD Men Women
(n = 133) (n = 43) (n = 44) (n = 46) (n = 86) (n = 47)
MMSE
Model 1 –0.023 0.084 0.103 0.021 0.144 –0.242
(–0.196; 0.150) (–0.238; 0.405) (–0.203; 0.410) (–0.288; 0.329) (–0.072; 0.360) (–0.537; 0.053)
Model 2 –0.045 0.111 0.095 –0.017 0.121 –0.210
(–0.209; 0.120) (–0.231; 0.454) (–0.200; 0.390) (–0.322; 0.288) (–0.092; 0.333) (–0.481; 0.061)
Model 3 –0.071 0.175 0.045 –0.014 0.123 –0.483∗
(–0.252; 0.111) (–0.190; 0.540) (–0.323; 0.413) (–0.352; 0.324) (–0.108; 0.354) (–0.831; –0.135)
Composite memory score
Model 1 –0.051 –0.324∗ 0.164 0.210 0.120 –0.206
(–0.224; 0.122) (–0.619; –0.030) (–0.143; 0.472) (–0.091; 0.511) (–0.085; 0.324) (–0.489; 0.078)
Model 2 –0.048 –0.251 0.170 0.162 0.078 –0.174
(–0.206; 0.109) (–0.549; 0.047) (–0.103; 0.444) (–0.143; 0.467) (–0.108; 0.264) (–0.434; 0.086)
Model 3 –0.014 –0.092 0.162 0.251 0.150 –0.273
(–0.188; 0.159) (–0.381; 0.197) (–0.177; 0.502) (–0.078; 0.580) (–0.048; 0.347) (–0.628; 0.081)
Data are presented as standardized regression coefficients, which reflect the standard deviation change in cognitive performance per standard
deviation increase in cerebrospinal fluid insulin levels. Insulin levels were transformed with the natural logarithm prior to analysis. Stratified
analyses according to sex were performed as interaction analyses revealed statistically significant interaction of this factor on the association
between CSF insulin and cognitive performance. ∗p < 0.05. Model 1: adjusted for UMC; Model 2: additionally adjusted for age and sex
(the latter not in case of stratified analysis according to sex); Model 3: additionally adjusted for BMI and the presence of diabetes. CSF,
cerebrospinal fluid; SCI, subjective cognitive impairment; aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; UMC,
University Medical Center; BMI, body mass index.
diagnostic groups was borderline significant (p for
trend = 0.059). There were no interactions with sex
or APOE 4 genotype (p for interaction = 0.707 and
0.120, respectively). When diabetes status and body
mass index were included as covariates, pairwise
comparisons between the diagnostic groups con-
firmed that CSF insulin did not differ significantly
between the groups (all p > 0.105).
CSF insulin and cognitive performance
Table 3 shows the association of CSF insulin with
cognitive performance across the groups and within
each diagnostic group. After adjustment for center,
CSF insulin was not associated with cognitive per-
formance in the overall study population, nor within
the groups of individuals with aMCI or AD. Among
individuals with SCI, higher CSF insulin levels were
associated with worse memory function, but this
association lost significance once adjustments were
made for age and sex.
Multiplicative interaction analyses revealed that
the null associations between CSF insulin and cog-
nitive performance did not differ by the presence of
diabetes (all p for interaction >0.614) or APOE 4
genotype (all p > 0.425), but did differ by sex (all
p < 0.059). Subsequent stratified analyses (Table 3,
right panel) showed that among women, but not
among men, higher CSF insulin were associated with
worse cognitive performance. These associations
were significant for MMSE performance in the fully
adjusted model.
CSF insulin and CSF biomarkers of AD
Table 4 shows the associations of CSF insulin with
CSF biomarkers of AD across and within each diag-
nostic group. In brief, CSF insulin was not associated
with CSF A1-42, nor with levels of Tau or p-Tau.
Multiplicative interaction analyses showed that
diabetes did not modify these null associations (all
p for interaction >0.170), while sex and APOE 4
genotype did, at least for the association between CSF
insulin and (p-)Tau (all p < 0.017 and <0.096, respec-
tively). Subsequent stratified analyses (Table 4, right
panel) showed that among women, but not among
men, higher CSF insulin levels were associated with
higher levels of tau and tended to be associated with
higher levels of p-Tau in the fully adjusted model. In
APOE 4 non-carriers, but not in carriers, higher CSF
insulin was associated with both higher tau and p-Tau
levels in the fully adjusted model. Notably, associa-
tions were strongest among female patients who were
non-carriers of the APOE 4 allele (data not shown).
Sensitivity analysis
When the data were reanalyzed excluding individ-
uals with diabetes, qualitatively similar results were
obtained (Supplementary Tables 2 and 3).
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Table 4
Associations of CSF insulin levels with levels of CSF A1-42 and (p-)Tau
Total SCI aMCI AD Men Women APOE 4 APOE 4
(n = 138) (n = 45) (n = 44) (n = 49) (n = 90) (n = 48) carriers non-carriers
(n = 81) (n = 57)
CSF A1-42
Model 1 –0.013 –0.006 0.057 0.118 . . . . . . . . . . . .
(–0.183; 0.157) (–0.320; 0.309) (–0.258; 0.373) (–0.167; 0.403)
Model 2 –0.023 –0.034 0.061 0.087 . . . . . . . . . . . .
(–.185; 0.139) (–0.354; 0.285) (–0.245; 0.366) (–0.204; 0.378)
Model 3 –0.130 –0.001 –0.185 –0.059 . . . . . . . . . . . .
(–0.303; 0.043) (–0.355; 0.353) (–0.519; 0.149) (–0.362; 0.245)
CSF Tau
Model 1 0.006 0.171 –0.200 –0.119 –0.184 0.236 –0.147 0.253
(–0.164; 0.177) (–0.139; 0.481) (–0.495; 0.096) (–0.414; 0.177) (–0.394; 0.026) (–0.055; 0.528) (–0.370; 0.077) (–0007; 0.513)
Model 2 0.012 0.097 –0.202 –0.114 –0.147 0.194 –0.137 0.232∗
(–0.140; 0.164) (–0.165; 0.359) (–0.466; 0.062) (–0.412; 0.185) (–0.335; 0.040) (–0.071; 0.459) (–0.347; 0.074) (0.014; 0.450)
Model 3 0.059 0.189 –0.060 –0.133 –0.098 0.311 –0.189 0.287∗
(–0.104; 0.222) (–0.089; 0.467) (–0.361; 0.241) (–0.462; 0.196) (–0.297; 0.101) (–0.030; 0.653) (–0.441; 0.063) (0.079; 0.495)
CSF p-Tau
Model 1 0.037 0.165 –0.162 –0.067 –0.174 0.287∗ –0.073 0.224
(–0.131; 0.206) (–0.140; 0.471) (–0.473; 0.150) (–0.358; 0.225) (–0.383; 0.035) (0.003; 0.571) (–0.294; 0.148) (–0.042; 0.490)
Model 2 0.039 0.097 –0.164 –0.069 –0.145 0.246 –0.066 0.201
(–0.116; 0.195) (–0.184; 0.377) (–0.455; 0.127) (–0.369; 0.231) (–0.340; 0.051) (–0.013; 0.505) (–0.282; 0.150) (–0.028; 0.430)
Model 3 0.074 0.207 –0.036 –0.100 –0.088 0.353∗ –0.105 0.246∗
(–0.090; 0.239) (–0.082; 0.497) (–0.370; 0.298) (–0.426; 0.225) (–0.290; 0.113) (0.018; 0.689) (–0.360; 0.149) (0.026; 0.467)
Data are presented as standardized regression coefficients, which reflect the standard deviation change in cerebrospinal fluid levels of A1-42 and (p-)Tau per standard deviation increase in
cerebrospinal fluid insulin levels. Insulin and (p-)Tau levels were transformed with the natural logarithm prior to analysis. ∗p < 0.05. Stratified analyses according to sex and APOE 4 genotype
were performed as interaction analyses revealed statistically significant interaction of these variables on the association between CSF insulin and CSF (p-)Tau. Model 1: adjusted for UMC; Model
2: additionally adjusted for age and sex (the latter not in case of stratified analysis according to sex); Model 3: additionally adjusted for BMI and the presence of diabetes. CSF, cerebrospinal fluid;
SCI, subjective cognitive impairment; aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; A1-42, amyloid-1-42; Tau, total Tau; p-Tau, phosphorylated Tau; UMC, University
Medical Center; BMI, body mass index.
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DISCUSSION
The present study shows that, among women and
non-carriers of the APOE 4 allele, higher levels of
CSF insulin were associated with worse cognitive
performance and/or higher levels of CSF (p-)Tau.
CSF insulin did, however, not differ between diagnos-
tic groups of cognitive impairment (i.e., SCI, aMCI,
and AD). These findings add to the growing body of
evidence indicating that abnormal insulin signaling
is involved in AD [1–4] and also provide an explana-
tion for why women and non-carriers of the APOE
4 allele seem to benefit most from intranasal insulin
administration to enhance cognitive performance (in
AD) [24–26].
There are few earlier studies on the association
between CSF insulin and AD [17–21]. Results on
CSF insulin levels in patients with AD were incon-
sistent and reported CSF insulin to be increased [17],
decreased [18, 20], or unchanged [19, 21] in indi-
viduals with AD as compared to healthy individuals
[17–19, 21] or those with SCI [20]. The most probable
explanation for these variable results across studies
is the use of different study populations. For exam-
ple, studies reporting decreased levels of CSF insulin
in AD [18, 20] excluded individuals with diabetes,
while the present study provides evidence that the
presence of diabetes is associated with higher levels
of CSF insulin. Other differences between the popu-
lations concern the severity of the dementia and the
use of different reference groups.
Substantially more research has been conducted on
the association between cerebral glucose metabolism,
based on fluorodeoxyglucose positron emission
tomography (FDG-PET) [36–42] or the CSF to
plasma glucose ratio [43], and AD pathology.
Collectively, these studies suggest that cerebral
hypometabolism is more prominent in individuals
with AD [42] and is associated with higher CSF
(p-)Tau [36–39] and lower CSF A1-42 [36, 38, 40,
41, 43] levels. Although it has been suggested that
cerebral hypometabolism may reflect cerebral insulin
resistance [43], it is important to realize that glu-
cose uptake in the brain is largely independent of
insulin levels [44] Even in the hippocampus, one of
the brain regions with the highest concentrations of
insulin sensitive GLUT-4 receptors, it is believed that
glucose update does not necessary require insulin
[44]. The link between cerebral hypometabolism and
AD does, thus, not directly support a role for insulin
resistance in AD pathology. This is particularly the
case because glucose itself may have a direct effect
on tau metabolism [45] and because it has been
suggested that tau-related pathology may precede
cerebral hypometabolism rather than being a conse-
quence of it [46].
Despite the numerous reviews that have been pub-
lished on the mechanisms through which cerebral
insulin might interfere with A and tau metabolism
(e.g., [4, 47]), only one previous study has actu-
ally evaluated CSF insulin in relation to CSF A1-42
and (p-)Tau levels [20]. The overall null results of
that study are in line with the null associations we
observed in our overall study population. We, how-
ever, now show that higher levels of CSF insulin
were associated with higher levels of CSF (p-)Tau
in women and non-carriers of the APOE 4 allele,
which reinforces data from experimental studies
linking insulin to tau metabolism. From a pathophys-
iological viewpoint, higher levels of CSF insulin,
potentially reflecting cerebral insulin resistance and
thus deficient brain insulin signaling, may result in
reduced activity of the phosphoinositide 3-kinase-
protein kinase B pathway. This, in turn, leads to over
activation of glycogen synthase kinase-3, and conse-
quently, hyperphosphorylation of tau [47]. That the
association between CSF insulin and tau differs with
APOE 4 genotype could be explained by a higher
degree of insulin resistance among non-carriers rela-
tive to carriers of the APOE 4 allele, as illustrated by
differences in insulin-mediated glucose disposal rates
[16]. Alternatively, a potential association between
CSF insulin and tau in APOE 4 carriers might have
been simply overshadowed by the high AD risk asso-
ciated with APOE 4 carriership.
The sex differences observed in our study are in
line with experimental data and clinical studies show-
ing that the brains of men and women are differen-
tially sensitive to the effects of insulin [23, 24, 48, 49].
More specifically, previous studies have shown that
the anorexigenic effects of intranasally administered
insulin are more prominent in men, while its memory
enhancing effects are more prominent women. It has
been suggested [24] that these sex differences can be
explained by the cognitive effects of estrogen [50].
A more recent study, however, showed that young
and postmenopausal women are comparable sensi-
tivity to the memory enhancing effects of intranasal
insulin [51], which reiterates that estrogen explains
the observed sex differences. What explains these dif-
ferences should be explored in future studies. Perhaps
it may relate to other physiological or anatomical fac-
tors that differ between sexes, for example the density
of hippocampal insulin receptors.
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Notably, we did not observe any association
between CSF levels of insulin and A, while a previ-
ous study noted that a single dose of intranasal insulin
increased plasma levels of the short form of A (i.e.,
A40) [52]. A potential explanation for this finding
are the complex and dual effects insulin (signaling)
may have on A clearance [4]. On the one hand,
insulin may promote A clearance by accelerating its
intraneuronal transport and increasing protein levels
of the insulin degrading enzyme (IDE), a metallo-
protease that is able to degrade A [4]. On the other
hand, IDE also catabolizes insulin, for which it has a
higher affinity, which means that insulin at the same
time can inhibit A degradation [4]. An alternative
explanation is that cerebral insulin is involved in AD
via pathways other than A metabolism (reviewed
in [33]).
The present study has limitations. First and fore-
most, CSF samples were not necessarily taken in the
fasting state, nor was lumbar puncture performed at a
fixed time of the day. The time of day at which lum-
bar puncture was performed was also not recorded
in the database. Hence, we were unable to adjust
our analyses for potential biorhythm effects, while
the production and secretion of at least insulin [53]
and A [54] seem to follow a circadian rhythm.
Although this may have led us to underestimate the
association of CSF insulin with AD pathology, it is
unlikely to explain the observed modulating effects
of either sex or APOE 4 genotype. A second lim-
itation that may have further affected our estimates
of the association between CSF insulin and CSF p-
Tau concerns the use of an antibody for p-Tau that
was specific for phosphorylation at threonine 181,
while deficient insulin signaling leads to a widespread
phosphorylation of tau at multiple sites. Next, it
can be questioned whether higher CSF insulin levels
reflect cerebral insulin resistance the way hyperin-
sulinemia in the plasma reflects peripheral insulin
resistance. Note, however, that individuals with dia-
betes, who are the most likely to have cerebral
insulin resistance despite the fact that cerebral and
peripheral resistance not necessarily concur [13], had
higher levels of CSF insulin. Fourth, multiple anal-
yses were performed without correction for multiple
testing, though stratified analyses were only per-
formed in case of statistically significant interaction
with a clear a priori hypothesis. Fifth, in the cur-
rent study, no blood samples were analyzed. Such
data would have provided valuable information on
how peripheral and cerebral insulin metabolism may
interact in relation to cognitive performance and AD
pathology, although compartmentalization is also
possible. Finally, it can be questioned whether the
composition of the CSF is directly comparable to
that of the brain’s interstitial fluid [51]. Undoubtedly,
however, CSF insulin is a better indicator of deficient
brain signaling than blood-derived markers.
In conclusion, our results indicate that higher
CSF insulin levels are related to impairment in cog-
nitive performance and biomarkers of AD among
women and non-carriers of the APOE 4 allele. As
such, our data suggest that the potential involvement
of cerebral insulin (resistance) in the pathogene-
sis of AD is not uniform across individuals. Future
studies are needed to determine whether endoge-
nous high CSF insulin levels indeed reflect cerebral
insulin resistance, as this might have implications
for selection of patients who may benefit from the
intranasal use of insulin to improve or preserve cog-
nitive performance. Longitudinal studies are required
to strengthen the pathophysiological relevance of our
findings.
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